Who is sponsoring NCT00041795?

NCT00041795 is sponsored by NeoTherapeutics.

What drugs are being tested in NCT00041795?

Interventions in NCT00041795: leteprinim potassium (Neotrofin).

What condition does NCT00041795 study?

NCT00041795 studies Peripheral Nervous System Diseases, Chemotherapy-Induced Peripheral Neuropathy.

Is NCT00041795 still recruiting?

NCT00041795 is currently completed. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00041795

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer

Completed Phase 2 Last updated 23 June 2005

What this trial tests

Phase 2 trial testing leteprinim potassium (Neotrofin) in Peripheral Nervous System Diseases in 50 participants. Completed.

Timeline

1 January 2002

Quick facts

Lead sponsor	NeoTherapeutics
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	1 January 2002
Sites	6 locations across United States

Drugs / interventions tested

leteprinim potassium (Neotrofin) — full drug profile →

Conditions studied

Peripheral Nervous System Diseases — all drugs for Peripheral Nervous System Diseases →
Chemotherapy-Induced Peripheral Neuropathy — all drugs for Chemotherapy-Induced Peripheral Neuropathy →

Sponsor

NeoTherapeutics — full company profile →

Who can join

Adults 18 to 80, any sex, with Peripheral Nervous System Diseases or Chemotherapy-Induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool.
Quintão NLM, Santin JR, Stoeberl LC, Corrêa TP, et al · · 2019 · cited 59× · PMID 31555078 · DOI 10.3389/fnins.2019.00907
Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.
Bordet T, Pruss RM. · · 2009 · cited 17× · PMID 19789070 · DOI 10.1016/j.nurt.2009.07.001

Verify or expand the search:

Other recruiting trials for Peripheral Nervous System Diseases

Currently open trials in the same condition.

NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06835634 — Progressive Advancements in Neurosurgery, Data and Analysis Database · active not recruiting
NCT04800484 — The Effects of AFO Heel Height and Stiffness on Gait · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00041795 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NeoTherapeutics
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00041795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing